Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/0008-5472.CAN-16-2822 http://scihub22266oqcxt.onion/10.1158/0008-5472.CAN-16-2822 C5413372!5413372 !28302680     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28302680 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cancer+Res 2017 ; 77 (9 ): 2255-2265 Nephropedia Template TP {{tp|p=28302680 |t=2017. Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma |pdf=|usr=}}{{28302680 }} gab.com Text Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma JO: Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=28302680 #FOAvip Understanding the intratumoral heterogeneity of hepatocellular carcinoma is instructive for developing personalized therapy and identifying molecular biomarkers. Here we applied whole-exome sequencing to 69 samples from 11 patients to resolve the genetic architecture of subclonal diversification. Spatial genomic diversity was found in all 11 hepatocellular carcinoma cases, with 29% of driver mutations being heterogeneous, including TERT, ARID1A, NOTCH2, and STAG2. Similar with other cancer types, TP53 mutations were always shared between all tumor regions, that is, located on the "trunk" of the evolutionary tree. In addition, we found that variants within several drug targets such as KIT, SYK, and PIK3CA were mutated in a fully clonal manner, indicating their therapeutic potentials for hepatocellular carcinoma. Temporal dissection of mutational signatures suggested that mutagenic processes associated with exposure to aristolochic acid and aflatoxin might play a more important role in early, as opposed to late, stages of hepatocellular carcinoma development. Moreover, we observed extensive intratumoral epigenetic heterogeneity in hepatocellular carcinoma based on multiple independent analytical methods and showed that intratumoral methylation heterogeneity might play important roles in the biology of hepatocellular carcinoma cells. Our results also demonstrated prominent heterogeneity of intratumoral methylation even in a stable hepatocellular carcinoma genome. Together, these findings highlight widespread intratumoral heterogeneity at both the genomic and epigenomic levels in hepatocellular carcinoma and provide an important molecular foundation for better understanding the pathogenesis of this malignancy. Cancer Res; 77(9); 2255-65. ©2017 AACR. Twit Text FOAVip Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma ????Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=28302680 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28302680 #FOAvip English Wikipedia <ref>{{Cite pmid|28302680 }}</ref> Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma #MMPMID28302680 Lin DC ; Mayakonda A ; Dinh HQ ; Huang P ; Lin L ; Liu X ; Ding LW ; Wang J ; Berman BP ; Song EW ; Yin D ; Koeffler HP Cancer Res 2017[May]; 77 (9 ): 2255-2265 PMID28302680 show ga Understanding the intratumoral heterogeneity of hepatocellular carcinoma is instructive for developing personalized therapy and identifying molecular biomarkers. Here we applied whole-exome sequencing to 69 samples from 11 patients to resolve the genetic architecture of subclonal diversification. Spatial genomic diversity was found in all 11 hepatocellular carcinoma cases, with 29% of driver mutations being heterogeneous, including TERT, ARID1A, NOTCH2, and STAG2. Similar with other cancer types, TP53 mutations were always shared between all tumor regions, that is, located on the "trunk" of the evolutionary tree. In addition, we found that variants within several drug targets such as KIT, SYK, and PIK3CA were mutated in a fully clonal manner, indicating their therapeutic potentials for hepatocellular carcinoma. Temporal dissection of mutational signatures suggested that mutagenic processes associated with exposure to aristolochic acid and aflatoxin might play a more important role in early, as opposed to late, stages of hepatocellular carcinoma development. Moreover, we observed extensive intratumoral epigenetic heterogeneity in hepatocellular carcinoma based on multiple independent analytical methods and showed that intratumoral methylation heterogeneity might play important roles in the biology of hepatocellular carcinoma cells. Our results also demonstrated prominent heterogeneity of intratumoral methylation even in a stable hepatocellular carcinoma genome. Together, these findings highlight widespread intratumoral heterogeneity at both the genomic and epigenomic levels in hepatocellular carcinoma and provide an important molecular foundation for better understanding the pathogenesis of this malignancy. Cancer Res; 77(9); 2255-65. ©2017 AACR. |*Genomics [MESH] |Adult [MESH] |Aged [MESH] |Carcinoma, Hepatocellular/*genetics/pathology [MESH] |DNA Copy Number Variations/genetics [MESH] |DNA Mutational Analysis [MESH] |Exome/genetics [MESH] |Female [MESH] |Genetic Heterogeneity [MESH] |High-Throughput Nucleotide Sequencing [MESH] |Humans [MESH] |Liver Neoplasms/*genetics/pathology [MESH] |Male [MESH] |Middle Aged [MESH] |Mutation/genetics [MESH]Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma (epmc).pdf DeepDyve Pubget Overpricing